Photo of Michele R Hacker,  ScD

Michele R Hacker, ScD

Beth Israel Deaconess Medical Center

Beth Israel Deaconess Medical Center
Phone: (617) 667-2933


mhacker@bidmc.harvard.edu

Michele R Hacker, ScD

Beth Israel Deaconess Medical Center

EDUCATIONAL TITLES

  • Associate Professor, Obstetrics, Gynecology and Reproductive Biology, Harvard Medical School
  • Associate Professor, Epidemiology, Harvard T.H. Chan School Of Public Health
  • Vice Chair for Research, Obstetrics and Gynecology, Beth Israel Deaconess Medical Center

DF/HCC PROGRAM AFFILIATION

Research Abstract

Dr. Michele Hacker is an Associate Professor in the Department of Obstetrics, Gynecology and Reproductive Biology at Harvard Medical School and an Associate Professor in the Department of Epidemiology at Harvard T. H. Chan School of Public Health. She also is the Vice Chair for Research in the Department of Obstetrics and Gynecology at BIDMC, as well as Director of the Division of Research. While her research covers a wide range of substantive areas related to women’s health, she has focused primarily on pregnancy outcomes—with an emphasis on infertility and preterm birth. Recently, in collaboration with the Division of Gynecologic Oncology at BIDMC, Dr. Hacker has engaged in several research projects investigating the financial toxicity of gynecologic cancers, with an emphasis on ovarian cancer. Further, Dr. Hacker has a longstanding breast cancer collaboration with the Cancer Risk and Prevention Program at BIDMC. Dr. Hacker has served as principal investigator or co-investigator on multiple clinical and basic science research studies. She also serves as member of the institutional review board at BIDMC. Dr. Hacker devotes substantial effort to mentoring medical students, public health graduate students, residents, fellows and faculty to facilitate clinical research related to reproductive health. In addition, she has taught a variety of courses in epidemiology at the undergraduate and graduate level.

Publications from Harvard Catalyst Profiles

Powered by Harvard Catalyst
  • Iesato A, Li S, Roti G, Hacker MR, Fischer AH, Nucera C. Lenvatinib targets PDGFR-β pericytes and inhibits synergy with thyroid carcinoma cells: novel translational insights. J Clin Endocrinol Metab 2021. PubMed
  • Luckett R, Painter H, Hacker MR, Simon B, Seiphetlheng A, Erlinger A, Eakin C, Moyo S, Tumwine Kyokunda L, Esselen K, Feldman S, Morroni C, Ramogola-Masire D. Persistence and clearance of high-risk human papillomavirus and cervical dysplasia at one year in women living with human immunodeficiency virus: a prospective cohort study. BJOG 2021. PubMed
  • Esselen KM, Gompers A, Hacker MR, Bouberhan S, Shea M, Summerlin SS, Rucker LR, Huh WK, Pisu M, Liang MI. Evaluating meaningful levels of financial toxicity in gynecologic cancers. Int J Gynecol Cancer 2021. PubMed
  • Esselen KM, Stack-Dunnbier H, Gompers A, Hacker MR. Crowdsourcing to measure financial toxicity in gynecologic oncology. Gynecol Oncol 2021. PubMed
  • Tung N, Arun B, Hacker MR, Hofstatter E, Toppmeyer DL, Isakoff SJ, Borges V, Legare RD, Isaacs C, Wolff AC, Marcom PK, Mayer EL, Lange PB, Goss AJ, Jenkins C, Krop IE, Winer EP, Schnitt SJ, Garber JE. TBCRC 031: Randomized Phase II Study of Neoadjuvant Cisplatin Versus Doxorubicin-Cyclophosphamide in Germline Carriers With HER2-Negative Breast Cancer (the INFORM trial). J Clin Oncol 2020. PubMed
  • Cervoni GE, Quintana L, Erlinger AL, Neo DT, Recht A, Schnitt SJ, Hacker MR, Sharma R. Local recurrence after breast-conserving therapy for phyllodes tumors: A 15-year retrospective review. Breast J 2019. PubMed
  • Ore AS, Shear MA, Liu FW, Dalrymple JL, Awtrey CS, Garrett L, Stack-Dunnbier H, Hacker MR, Esselen KM. Adoption of enhanced recovery after laparotomy in gynecologic oncology. Int J Gynecol Cancer 2019. PubMed
  • Luckett R, Mogowa N, Li HJ, Erlinger A, Hacker MR, Esselen K, Feldman S, Shapiro R, Morroni C, Ramogola-Masire D. Performance of Two-Stage Cervical Cancer Screening With Primary High-Risk Human Papillomavirus Testing in Women Living With Human Immunodeficiency Virus. Obstet Gynecol 2019; 134:840-849. PubMed
  • Modest AM, Johnson KM, Karumanchi SA, Resetkova N, Young BC, Fox MP, Wise LA, Hacker MR. Risk of ischemic placental disease is increased following in vitro fertilization with oocyte donation: a retrospective cohort study. J Assist Reprod Genet 2019. PubMed
  • Bouberhan S, Shea M, Kennedy A, Erlinger A, Stack-Dunnbier H, Buss MK, Moss L, Nolan K, Awtrey C, Dalrymple JL, Garrett L, Liu FW, Hacker MR, Esselen KM. Financial toxicity in gynecologic oncology. Gynecol Oncol 2019; 154:8-12. PubMed
  • Humphries LA, Dodge LE, Kennedy EB, Humm KC, Hacker MR, Sakkas D. Is younger better? Donor age less than 25 does not predict more favorable outcomes after in vitro fertilization. J Assist Reprod Genet 2019. PubMed
  • Jorgensen EM, Modest AM, Hur HC, Hacker MR, Awtrey CS. Hysterectomy Practice Patterns in the Postmorcellation Era. Obstet Gynecol 2019; 133:643-649. PubMed
  • Lightfoot MDS, Esselen KM, Haviland MJ, Dalrymple JL, Awtrey CS, Garrett LA, Hacker MR, Liu FW. Participation in global health delivery: Survey results from the Society of Gynecologic Oncology. Gynecol Oncol Rep 2018; 26:7-10. PubMed
  • Mamtani A, Gonzalez JJ, Neo DT, Friedman RS, Recht A, Hacker MR, Sharma R. Treatment Strategies in Octogenarians with Early-Stage, High-Risk Breast Cancer. Ann Surg Oncol 2018. PubMed
  • Von Bargen EC, Grimes CL, Mishra K, Wang R, Haviland MJ, Hacker MR, Carnevale JA, Estes AJ, Elkadry EA. Prevalence of occult pre-malignant or malignant pathology at the time of uterine morcellation for benign disease. Int J Gynaecol Obstet 2017; 137:123-128. PubMed
  • Mamtani A, Gonzalez JJ, Neo D, Slanetz PJ, Houlihan MJ, Herold CI, Recht A, Hacker MR, Sharma R. Early-Stage Breast Cancer in the Octogenarian: Tumor Characteristics, Treatment Choices, and Clinical Outcomes. Ann Surg Oncol 2016. PubMed
  • Humphries LA, Chang O, Humm K, Sakkas D, Hacker MR. Influence of race and ethnicity on in vitro fertilization outcomes: systematic review. Am J Obstet Gynecol 2016; 214:212.e1-212.e17. PubMed
  • Tung N, Garber JE, Hacker MR, Torous V, Freeman GJ, Poles E, Rodig S, Alexander B, Lee L, Collins LC, Schnitt SJ. Prevalence and predictors of androgen receptor and programmed death-ligand 1 in -associated and sporadic triple-negative breast cancer. NPJ Breast Cancer 2016; 2:16002. PubMed
  • Tung N, Gaughan E, Hacker MR, Lee LJ, Alexander B, Poles E, Schnitt SJ, Garber JE. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers. Breast Cancer Res Treat 2014. PubMed
  • Malizia BA, Dodge LE, Penzias AS, Hacker MR. The cumulative probability of liveborn multiples after in vitro fertilization: a cohort study of more than 10,000 women. Fertil Steril 2013; 99:393-9. PubMed
  • Lannon BM, Choi B, Hacker MR, Dodge LE, Malizia BA, Barrett CB, Wong WH, Yao MW, Penzias AS. Predicting personalized multiple birth risks after in vitro fertilization-double embryo transfer. Fertil Steril 2012; 98:69-76. PubMed
  • Liu FW, Vwalika B, Hacker MR, Allen S, Awtrey CS. Cervical cancer and HPV vaccination: Knowledge and attitudes of adult women in Lusaka, Zambia. J Vaccines Vaccin 2012. PubMed
  • Ogbechie OA, Hacker MR, Dodge LE, Patil MM, Ricciotti HA. Confusion regarding cervical cancer screening and chlamydia screening among sexually active young women. 2012; 88:35-7. PubMed
  • Malizia BA, Hacker MR, Penzias AS. Cumulative live-birth rates after in vitro fertilization. N Engl J Med 2009; 360:236-43. PubMed
  • Janco JM, Hacker MR, Konstantinopoulos PA, Cannistra SA, Awtrey CS. Laparoscopic intraperitoneal port placement for optimally cytoreduced advanced ovarian cancer. J Minim Invasive Gynecol ; 18:629-33. PubMed
Hide